Investor's Business Daily on MSN3mon
GSK Plummets To 10-Month Low As RSV, Shingles Vaccines Hit The Skids
GSK stock plunged to a 10-month low Wednesday after sales of its respiratory syncytial virus vaccine, Arexvy, skidded and ...
Nasdaq1mon
FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV Vaccines Abrysvo And Arexvy
(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome following ...
Pharm Exec1mon
FDA Mandates Updates to Prescribing Information for RSV Vaccines Abrysvo, Arexvy for Increased Guillain-Barré Syndrome Risk
Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...
Medical Xpress29d
FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk.
Fortune3mon
Emma Walmsley
Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine, which was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated $1.6 billion in sales in its ...